Grail Inc ((GRAL)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Grail Inc. is conducting a study titled ‘REACH Study: Galleri® in the Medicare Population.’ This multi-center comparative prospective cohort study aims to evaluate the real-world clinical impact, including safety and performance, of the Galleri® test, a blood-based multi-cancer early detection (MCED) test. The study is significant as it seeks to enroll a diverse participant pool, including 20% from under-represented minority groups.
The intervention being tested is the Galleri® Multi-Cancer Early Detection Test, a device designed to detect multiple types of cancer early through blood testing, with results returned to participants.
The study is interventional with a non-randomized, parallel assignment model. It includes two groups: one receiving the Galleri test plus usual care, and a comparator group receiving usual care alone. There is no masking involved, and the primary purpose is screening.
The study began on July 12, 2024, with an estimated completion date yet to be announced. The last update was submitted on August 5, 2025, indicating ongoing recruitment and progress.
This study update could influence Grail Inc.’s stock performance positively, as successful results may enhance investor confidence and market position in the competitive cancer detection industry. The involvement of a diverse participant group may also bolster the test’s credibility and appeal.
The study is ongoing, with further details available on the ClinicalTrials portal.